Journal of Neuroimmune Pharmacology

, Volume 8, Issue 4, pp 757–759 | Cite as

Commentary on Special Issue: CNS Diseases and the Immune System

  • Bert A. ‘t HartEmail author
  • Wilfred F. den Dunnen


In an increasing number of central nervous system (CNS) diseases a pathogenic contribution of the immune system is proposed. However, the exact underlying mechanisms are often poorly understood. The collection of articles in this special issue presents a state-of-the-art review of adaptive and innate immune mechanisms and their main players in number CNS disorders. The aim of these articles is to stimulate discussion on the question whether the immune system may be a feasible target of therapy for diseases where currently no effective treatment exists.


Neuroinflammation Neurodegeneration Adaptive immunity Innate immunity 


Conflict of interest

The authors report no conflict of interest.


  1. Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61:288–299PubMedCrossRefGoogle Scholar
  2. Gabibov AG, Belogurov AA Jr, Lomakin YA, Zakharova MY, Avakyan ME, Dubrovskaya VV, Smirnov IV, Ivanov AS, Molnar AA, Gurtsevitch VE, Diduk SV, Smirnova KV, Avalle B, Sharanova SN, Tramontano A, Friboulet A, Boyko AN, Ponomarenko NA, Tikunova NV (2011) Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. FASEB J 25:4211–4221PubMedCrossRefGoogle Scholar
  3. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3:940–943PubMedCrossRefGoogle Scholar
  4. Lunemann JD, Kamradt T, Martin R, Munz C (2007) Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol 81:6777–6784PubMedCrossRefGoogle Scholar
  5. ‘t Hart BA, Abbott DH, Nakamura K, Fuchs E (2012) The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov Today 17(21–22):1160-1165Google Scholar
  6. ‘t Hart BA, Jagessar SA, Haanstra K, Verschoor E, Laman JD, Kap YS (2013) The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis. Front Immunol in pressGoogle Scholar
  7. ‘t Hart BA, Hintzen RQ, Laman JD (2009) Multiple sclerosis—a response-to-damage model. Trends Mol Med 15:235–244PubMedCrossRefGoogle Scholar
  8. Wilkin TJ (1990) The primary lesion theory of autoimmunity: a speculative hypothesis. Autoimmunity 7:225–235PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department ImmunobiologyBiomedical Primate Research CentreRijswijkThe Netherlands
  2. 2.Department NeuroscienceUniversity Medical Center GroningenGroningenThe Netherlands
  3. 3.Department PathologyUniversity Medical Center GroningenGroningenThe Netherlands

Personalised recommendations